Breast Cancer: New targeted therapies transform treatment - KOL Insight

Breast Cancer: New targeted therapies transform treatment - KOL Insight

Regular price $4,995.00 Sale

Published on Feb 10, 2014 - 153 pages

The introduction of targeted therapies revolutionised the breast cancer market, widening clinical options and bringing improved survival rates and lower side effects for patients. Now the sector is set for further positive change and expansion as next generation products for HER2-positive disease come to market, and CDK4/6 and P13K inhibitors hold the prospect of new treatments for hormone receptor-positive and HER2-negative breast cancer patients - an area of huge unmet clinical need. Which are the companies and products that will change the commercial and clinical landscape over the next 5 years?

Among the main drivers of change in the breast cancer market...

Roche's Kadcyla and Perjeta set to transform the treatment of HER2-positive breast cancer

Roche's Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab) are both viewed as significant steps forward in the treatment of breast cancer. When added to Herceptin (trastuzumab), Perjeta is the first drug to improve survival in the first-line setting since the availability of Herceptin in 1998. Kadcyla is the first antibody-drug conjugate for the treatment of breast cancer and improves overall survival by almost six months in the second-line setting. To Roche's commercial benefit, both drugs are set to expand their indications and will likely dominate the market in both the early stages and first lines of treatment for metastatic


No room for biosimilar Herceptin?

Although the availability of biosimilar versions of Herceptin will likely expand in the near future, their prospects are not bright. Kadcyla and Perjeta look set to overtake Herceptin in the early stages and first-line treatment of metastatic HER2-positive breast cancer, thereby limiting the role of biosimilar trastuzumab. Furthermore, Roche's subcutaneous Herceptin offers more convenient administration than intravenous biosimilar versions. Clinical scepticism and defensive pricing will further limit the prospects for biosimilars in established markets.New approaches will transform the treatment of hormone receptor-positive and HER2-negative breast cancerWhile Novartis' Afinitor (everolimus) improves progression-free survival in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, it is highly toxic. Interest is now focussed on promising late-stage pipeline candidates. Pfizer's palbociclib and Novartis' LEE011 are locked in a race to become the first-to-market CDK4/6 inhibitor. Both drugs are expected to improve survival when combined with an aromatase inhibitor in the first-line treatment of this patient segment and at a lower cost in terms of toxicity. The treatment of hormone receptor-positive, HER2-negative breast cancer will be transformed by the availability of these and PI3K inhibitors such as Pfizer's buparlisib (BKM120).

Unique insider clinical opinion

This new KOL Insight report Breast Cancer -new targeted therapies transform treatment provides everyone interested in this dynamic cancer sector with a complete understanding of the targeted products which are shaping the current landscape and the research which will change future treatment paradigms.

Every aspect of the report is informed by insights gained from thorough 60-minute interviews with 12 experienced key opinion leaders (KOLs) from across major markets to provide expert views on the current treatment landscape and how it will change in the future. KOLs are selected based on their clinical experience, authored scientific publications, involvement in clinical trials and with the Pharma industry, their participation in treatment guideline development, and their record of presenting at high-profile international conferences. They bring incisive, expert "real world" insights to this fast changing sector.

This report tackles the pressing issues and questions in the breast cancer treatment market:

Which drug is the treatment of choice for each patient segment, line of therapy and unique patient characteristic, and what product attributes contribute to the preference, e.g. first-line treatment of HER2-positive, hormone receptor-positive and HER2-negative, or triple negative disease, and patients with brain metastases?

How is the product perceived by the medical community in terms of efficacy, tolerability, ease of administration, and other product attributes, and how does it compare with other treatment options?

Which recently completed or ongoing clinical trials have the greatest potential to impact prescribing trends and how will the results impact practice in the future, e.g. BOLERO-2, ALTTO, NeoALTTO, MARIANNE, APHINITY, KATHERINE, RESILIENCE, PALOMA-2, etc.?

What will a product need to show in order to become the treatment of choice in a specific patient segment and line of therapy and is it likely the product will meet these requirements?

How will the use of each product change in the future in terms of patient segments, line of therapy and preference, e.g. Roche's Herceptin, Perjeta, and Kadclya, GlaxoSmithKline's Tykerb, and Novartis' Afinitor?

What will the pipeline products need to show in terms of efficacy and tolerability endpoints to effectively compete with current therapies, and what is the likelihood the pipeline products will achieve those endpoints?

Which pipeline products are the most promising and how will they impact current players in the market e.g. Pfizer's CDK4/6 inhibitor palbociclib (PD 0332991), Novartis' PI3K inhibitor buparlisib (BKM120) and AstraZeneca's PARP inhibitor olaparib (AZD 2281)?

This report will allow you to:

  • Understand and evaluate the important drivers in targeted breast cancer treatments
  • <
  • Fully evaluate how the competitive landscape may change
  • <
  • Understand clinical opinions of current and futures products and how they will change treatment algorithms
  • <
  • Survey and appraise the late-stage product pipeline
  • KOL Insight Benefits
    • Understand and assess future breast cancer market developments
    • Analyse current and future treatment algorithms
    • Understand the strengths and weaknesses of currently available targeted therapies for breast cancer
    • Assess how prescribing trends will change with launch of new products
    • Identify promising late-stage pipeline products
    • Track KOL opinion continuously over the next 12 months
    Selected Quotes from the Report